Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Hemodynamic Responses to Provocative Maneuvers during Right Heart Catheterization
Montané, Bryce , Tonelli, Adriano R. , Arunachalam, Ambalavanan , Li, Manshi , Wang, Xiaofeng , Chaisson, Neal F. , Bhattacharyya, Anirban , Wang, Xiaofeng , Chaisson, Neal F , Tonelli, Adriano

Mayo Clinic

Annals of the American Thoracic Society | July 8, 2022 | Volume: 19 | Issue: 12 | Pages: 1977-1985

10.1513/annalsats.202201-077oc | PMID 35802812 Get It

Abstract Rationale Current guidelines recognize the utility of provocative maneuvers during right heart catheterization to aid the diagnosis of pulmonary hypertension. Few studies have compared the performance of different provocation maneuvers. Objectives To assess the hemodynamic correlation among three provocative maneuvers, including their effect on pulmonary hypertension classification. Methods This prospective trial was conducted between October 2016 and May 2018. Adult patients underwent three provocative maneuvers during right heart catheterization: passive leg raise (PLR), load-targeted supine bicycle exercise, and rapid crystalloid fluid infusion. Patients were classified as follows: no pulmonary hypertension, precapillary pulmonary hypertension, isolated postcapillary pulmonary hypertension, combined pre- and postcapillary pulmonary hypertension, and uncategorized pulmonary hypertension. We assessed the hemodynamic changes associated with each maneuver. We also assessed whether provocative maneuvers led to hemodynamic reclassification of the patient to either postcapillary pulmonary hypertension with provocation or exercise pulmonary hypertension. Results Eighty-five patients (mean age 62 ± 12 years, 53% women) were included. Correlation between exercise and fluid challenge was moderate to strong (0.49–0.82; P < 0.001) for changes in right atrial pressure, mean pulmonary arterial pressure, pulmonary arterial wedge pressure, and cardiac index from baseline. Correlation between PLR and exercise (0.4–0.65; P < 0.001) and between PLR and fluid challenge (0.45–0.6; P < 0.001) was moderate for changes in right atrial pressure, mean pulmonary arterial pressure, pulmonary arterial wedge pressure, pulmonary vascular resistance, and cardiac index. Hemodynamic correlation between other provocative maneuvers was poor. Depending on provocative maneuver and classification criteria, there was significant variation in the number of patients reclassified as having exercise pulmonary hypertension (3–50%) or postcapillary pulmonary hypertension with provocation (11–48%). Conclusions Hemodynamic determinations during exercise and fluid challenge showed moderate to strong hemodynamic correlation. Moderate hemodynamic correlation was seen between PLR and exercise or fluid challenge. Although some provocative maneuvers demonstrate good hemodynamic correlation, there is inconsistency when using these maneuvers to identify patients with postcapillary or exercise pulmonary hypertension.
Design and validation of a FHIR-based EHR-driven phenotyping toolbox
Brandt, Pascal , Pacheco, Jennifer A. , Adekkanattu, Prakash , Sholle, Evan , Stone, Daniel J. , Knaack, David, Xu, Zhenxing , Wang, Fei , Jiang, Guoqian , Pathak, Jyotishman , Brandt, Pascal S , Sholle, Evan T , Knaack, David M, Peng, Yifan , Benda, Natalie C , Luo, Yuan , Rasmussen, Luke V , Pacheco, Jennifer A , Abedian, Sajjad , Xu, Jie , Luo, Yuan , Rasmussen, Luke V.

Mayo Clinic

Journal of the American Medical Informatics Association | July 8, 2022 | Volume: 29 | Issue: 9 | Pages: 1449-1460

10.1093/jamia/ocac063 | PMID 35799370 Get It

Abstract Objectives To develop and validate a standards-based phenotyping tool to author electronic health record (EHR)-based phenotype definitions and demonstrate execution of the definitions against heterogeneous clinical research data platforms. Materials and Methods We developed an open-source, standards-compliant phenotyping tool known as the PhEMA Workbench that enables a phenotype representation using the Fast Healthcare Interoperability Resources (FHIR) and Clinical Quality Language (CQL) standards. We then demonstrated how this tool can be used to conduct EHR-based phenotyping, including phenotype authoring, execution, and validation. We validated the performance of the tool by executing a thrombotic event phenotype definition at 3 sites, Mayo Clinic (MC), Northwestern Medicine (NM), and Weill Cornell Medicine (WCM), and used manual review to determine precision and recall. Results An initial version of the PhEMA Workbench has been released, which supports phenotype authoring, execution, and publishing to a shared phenotype definition repository. The resulting thrombotic event phenotype definition consisted of 11 CQL statements, and 24 value sets containing a total of 834 codes. Technical validation showed satisfactory performance (both NM and MC had 100% precision and recall and WCM had a precision of 95% and a recall of 84%). Conclusions We demonstrate that the PhEMA Workbench can facilitate EHR-driven phenotype definition, execution, and phenotype sharing in heterogeneous clinical research data environments. A phenotype definition that integrates with existing standards-compliant systems, and the use of a formal representation facilitates automation and can decrease potential for human error.
Thyroid Disorders and Dementia Risk
Wieland, Daniel R. , Wieland, Julia R. , Wang, Han , Chen, Yi-Huei , Lin, Ching‐Heng , Wang, Jing‐Jie , Weng, Chien‐Hsiang

Mayo Clinic

Neurology | July 6, 2022 | Volume: 99 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000200740 | PMID 35794019 Get It

Radon descriptor-based machine learning using CT images to predict the fat tissue on left atrium in the heart
Deepa, Deepa, Singh, Yashbir , Hu, Wei-Chih, Wang, Ming Chen, Hu, Weichih , Singh, Yashbir

Mayo Clinic

Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine | July 6, 2022 | Volume: 236 | Issue: 8 | Pages: 1232-1237

10.1177/09544119221110657 | PMID 35791086 Get It

Heart disease has a higher fatality rate than any other disease. Increased Atrial fat on the left atrium has been discovered to cause Atrial Fibrillation (AF) in most patients. AF can put one’s life at risk and eventually lead to death. AF might worsen over time; therefore, it is crucial to have an early diagnosis and treatment. To evaluate the left atrium fat tissue pattern using Radon descriptor-based machine learning. This study developed a bridge between the Radon transform framework and machine learning to distinguish two distinct patterns. Motivated by a Radon descriptor-based machine learning approach, the patches of eight patients from CT images of the heart were used and categorized into “epicardial fat tissue” and “nonfat tissue” groups. The 10 feature vectors are extracted from each big patch using Radon descriptors and then fed into a traditional machine learning model. The results show that the proposed methodology discriminates between fat tissues and nonfat tissues clearly. KNN has shown the best performance with 96.77% specificity, 98.28% sensitivity, and 97.50% accuracy. To our knowledge, this study is the first attempt to provide a Radon transform-based machine learning method to distinguish between fat tissue and nonfat tissue on the left atrium. Our proposed research method could be potentially used in advanced interventions.
Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Agüera-Ortíz, Luis , Bruneau, Marie‐Andrée , Creese, Byron , D’Antonio, Fabrizia , Ismail, Zahinoor , Mortby, Moyra E. , Núñez, Nicolás A. , Oliveira, Fabricio Ferreira de , Pereiro, Arturo X. , Ravona‐Springer, Ramit , Rouse, Hillary J , Wang, Huali , Babulal, Ganesh M. , Fischer, Corinne Eleanor , Gatchel, Jennifer R. , Kumar, Sanjeev , McGeown, William J. , Lanctôt, Krista L.

Mayo Clinic

Journal of Alzheimer’s Disease | July 1, 2022 | Volume: 88 | Issue: 4 | Pages: 1203-1228

10.3233/jad-215483 | PMID 35786651 Get It

Psychotic phenomena are among the most severe and disruptive symptoms of dementias and appear in 30% to 50% of patients. They are associated with a worse evolution and great suffering to patients and caregivers. Their current treatments obtain limited results and are not free of adverse effects, which are sometimes serious. It is therefore crucial to develop new treatments that can improve this situation. We review available data that could enlighten the future design of clinical trials with psychosis in dementia as main target. Along with an explanation of its prevalence in the common diseases that cause dementia, we present proposals aimed at improving the definition of symptoms and what should be included and excluded in clinical trials. A review of the available information regarding the neurobiological basis of symptoms, in terms of pathology, neuroimaging, and genomics, is provided as a guide towards new therapeutic targets. The correct evaluation of symptoms is transcendental in any therapeutic trial and these aspects are extensively addressed. Finally, a critical overview of existing pharmacological and non-pharmacological treatments is made, revealing the unmet needs, in terms of efficacy and safety. Our work emphasizes the need for better definition and measurement of psychotic symptoms in dementias in order to highlight their differences with symptoms that appear in non-dementing diseases such as schizophrenia. Advances in neurobiology should illuminate the development of new, more effective and safer molecules for which this review can serve as a roadmap in the design of future clinical trials.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, Daniel A. , Hasserjian, Robert P. , Borowitz, Michael J., Kvasnicka, Hans Michael , Wang, Sa A. , Bagg, Adam , Barbui, Tiziano , Branford, Susan , Bueso‐Ramos, Carlos E. , Cortes, Jörge E. , Cin, Paola Dal , Dombret, Hervé , Duncavage, Eric J., Ebert, Benjamin L. , Estey, Elihu H. , Foucar, Kathryn , Gangat, Naseema , Gökbuget, Nicola , Hellström‐Lindberg, Eva , Beau, Michelle M. Le , Löwenberg, Bob , Malcovati, Luca , Odenike, Olatoyosi , Papaemmanuil, Elli , Porkka, Kimmo , Radich, Jerald P. , Reiter, Andreas , Rudelius, Martina , Schiffer, Charles A. , Sierra, Jorge , Stone, Richard M. , Tallman, Martin S. , Thiele, Jürgen, Tzankov, Alexandar , Wei, Andrew H. , Weinberg, Olga K. , Wierzbowska, Agnieszka , Cazzola, Mario , Tefferi, Ayalew , Hasserjian, Robert P , Kvasnicka, Hans-Michael , Barbui, Tiziano , Branford, Susan , Cortes, Jorge , DiNardo, Courtney , Ebert, Benjamin L , Gangat, Naseema , Gianelli, Umberto , Hobbs, Gabriela S , Larson, Richard A , Löwenberg, Bob , Macintyre, Elizabeth , Malcovati, Luca , Mullighan, Charles G , Niemeyer, Charlotte Marie , Ogawa, Seishi , Passamonti, Francesco , Porkka, Kimmo , Savona, Michael R , Schmitt-Graeff, Annette , Shimamura, Akiko , Vannucchi, Alessandro M , Vyas, Paresh , Wei, Andrew H , Wierzbowska, Agnieszka , Cazzola, Mario , Döhner, Hartmut , Tzankov, Alexandar , Arber, Daniel A , Orazi, Attilio , Calvo, Katherine R. , DiNardo, Courtney D. , Facchetti, Fabio , Gianelli, Umberto , Godley, Lucy A. , Gotlib, Jason , Hobbs, Gabriela , Hoffman, Ronald , Jabbour, Elias , Kiladjian, Jean‐Jacques , Larson, Richard A. , Loh, Mignon L. , Macintyre, Elizabeth , Mullighan, Charles G. , Órfão, Alberto , Passamonti, Francesco , Pui, Ching-Hon , Rozman, Marı́a , Savona, Michael R. , Stock, Wendy , Tien, Hwei‐Fang , Vannucchi, Alessandro M.

Mayo Clinic

Blood | June 29, 2022 | Volume: 140 | Issue: 11 | Pages: 1200-1228

10.1182/blood.2022015850 | PMID 35767897 Get It

Abstract The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
SHP2 inhibition enhances Yes-associated protein–mediated liver regeneration in murine partial hepatectomy models
Watkins, Ryan , Buckarma, EeeLN H. , Tomlinson, Jennifer L. , McCabe, Chantal E. , Yonkus, Jennifer A. , Werneburg, Nathan W., Bayer, Rachel L., Starlinger, Patrick , Robertson, Keith D. , Wang, Chen , Smoot, Rory L. , Smoot, Rory L , Robertson, Keith D , Wang, Chen , Starlinger, Patrick , Yonkus, Jennifer A , Buckarma, EeeLN , Tomlinson, Jennifer , Gores, Gregory J.

Mayo Clinic

JCI Insight | June 28, 2022 | Volume: 7 | Issue: 15 | Pages: No page available

10.1172/jci.insight.159930 | PMID 35763355 Get It

Disrupted liver regeneration following hepatectomy represents an “undruggable” clinical challenge associated with poor patient outcomes. Yes-associated protein (YAP), a transcriptional coactivator that is repressed by the Hippo pathway, is instrumental in liver regeneration. We have previously described an alternative, Hippo-independent mechanism of YAP activation mediated by downregulation of protein tyrosine phosphatase nonreceptor type 11 (PTPN11, also known as SHP2) inhibition. Herein, we examined the effects of YAP activation with a selective SHP1/SHP2 inhibitor, NSC-87877, on liver regeneration in murine partial hepatectomy models. In our studies, NSC-87877 led to accelerated hepatocyte proliferation, improved liver regeneration, and decreased markers of injury following partial hepatectomy. The effects of NSC-87877 were lost in mice with hepatocyte-specific Yap/Taz deletion, and this demonstrated dependence on these molecules for the enhanced regenerative response. Furthermore, administration of NSC-87877 to murine models of nonalcoholic steatohepatitis was associated with improved survival and decreased markers of injury after hepatectomy. Evaluation of transcriptomic changes in the context of NSC-87877 administration revealed reduction in fibrotic signaling and augmentation of cell cycle signaling. Cytoprotective changes included downregulation of Nr4a1 , an apoptosis inducer. Collectively, the data suggest that SHP2 inhibition induces a pro-proliferative and cytoprotective enhancement of liver regeneration dependent on YAP.
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Fasching, Peter A. , Liu, Duan , Scully, Steve, Ingle, James N. , Lyra, Paulo C. , Rack, Brigitte , Hein, Alexander , Ekici, Arif B. , Reis, André , Schneeweiß, Andreas , Tesch, Hans , Heinrich, Georg, Beckmann, Matthias W. , Ruebner, Matthias , Huebner, Hanna , Lambrechts, Diether , Madden, Ebony , Shen, Jess, Romm, Jane, Doheny, Kim, Jenkins, Gregory D. , Cunningham, Julie M. , Janni, Wolfgang , Schaid, Daniel J. , Häberle, Lothar , Weinshilboum, Richard M. , Wang, Liewei , Lambrechts, Diether , Lambrechts, Diether , Li, Liang , Fridley, Brooke L , Cunningham, Julie M , Janni, Wolfgang , Monteiro, Alvaro N , Ingle, J , Lambrechts, Diether , Hein, Alexander , Ekici, Arif B , Reis, André , Morais Lyra, Paulo Cilas , Liu, Duan , Fehm, Tanja , Carlson, Erin E. , Li, Liang , Fridley, Brooke L. , Monteiro, Álvaro N.A. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3342-3355

10.1158/1078-0432.ccr-20-4774 | PMID 35653140 Get It

Abstract Purpose: To identify molecular predictors of grade 3/4 neutropenic or leukopenic events (NLE) after chemotherapy using a genome-wide association study (GWAS). Experimental Design: A GWAS was performed on patients in the phase III chemotherapy study SUCCESS-A (n = 3,322). Genotyping was done using the Illumina HumanOmniExpress-12v1 array. Findings were functionally validated with cell culture models and the genotypes and gene expression of possible causative genes were correlated with clinical treatment response and prognostic outcomes. Results: One locus on chromosome 16 (rs4784750; NLRC5; P = 1.56E-8) and another locus on chromosome 13 (rs16972207; TNFSF13B; P = 3.42E-8) were identified at a genome-wide significance level. Functional validation revealed that expression of these two genes is altered by genotype-dependent and chemotherapy-dependent activity of two transcription factors. Genotypes also showed an association with disease-free survival in patients with an NLE. Conclusions: Two loci in NLRC5 and TNFSF13B are associated with NLEs. The involvement of the MHC I regulator NLRC5 implies the possible involvement of immuno-oncological pathways.